Death associated with CMV disease · solid organ transplant recipients
Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).
1 finding from 1 review
All‐cause death · solid organ transplant recipients
Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).
1 finding from 1 review
Acute rejection · solid organ transplant recipients
Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
1 finding from 1 review
Graft loss · solid organ transplant recipients
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
1 finding from 1 review
Opportunistic infections: other viral infections · solid organ transplant recipients
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
1 finding from 1 review
Leucopenia · solid organ transplant recipients
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
1 finding from 1 review
Kidney dysfunction · solid organ transplant recipients
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
1 finding from 1 review
CMV disease · solid organ transplant recipients
Ganciclovir leads to lower CMV disease compared with aciclovir (high certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes all‐cause mortality compared with liver transplantation (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir, epirubicin, multiple drugsϯ · healthcare staff who handle infusional hazardous drugs
It is very uncertain whether closed‐system transfer device plus safe handling changes irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir,… compared with safe handling alone (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Ganciclovir (B) versus acyclovir (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Low